Review Article
A Brief Drug Class Review: Considerations for Statin Use, Toxicity, and Drug Interactions
Abstract
Abstract: For approximately 30 years, statins have been effectively used to control cholesterol, thereby reducing the morbidity and mortality associated with cardiovascular disease. Evidence-based recommendations regarding how these drugs are dosed and used have changed significantly through the years. There are seven statins approved for use in the United States, and although the mechanism of action pertaining to cholesterol reduction is the same for all statins, each has its own specific pharmacologic profile. One unique aspect of statin dosing is understanding the potential drug interactions associated with statin use; interactions can occur with all statins, but the mechanism and type of interaction can vary significantly among drugs. These interactions can result in significant elevations in statin blood concentrations, thereby increasing the risk of the adverse effects of statins, the most significant of which is muscle toxicity. Practitioners who care for patients receiving statins should understand the pharmacologic differences among these drugs, as well as the varied drug interaction potential that all statins possess.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci 2010;8:484-493.
2. O’Sullivan S. Statins: a review of benefits and risks. https://www.tcd.ie/tsmj/archives/2007/Statins.pdf. Published 2007. Accessed October 22, 2017.
3. Srinivasa RK, Prasad T, Mohanta GP, et al. An overview of statins as hypolipidemic drugs. http://www.academia.edu/2672886/An_overview_of_statins_as_hypolipidemic_drugs._I. Published 2011. Accessed October 22, 2017.
4. Gulum AH, Hume AL. Statins: an update on clinical issues and selected adverse effects. http://www.npjournal.org/article/S1555-4155(14)00590-X/fulltext. Published 2015. Accessed October 22, 2017.
5. Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med 2001;5:378-387.
6. Miller PE, Martin SS. Approach to statin use in 2016: an update. Curr Atheroscler Rep 2016;18:20.
7. Lipid-lowering drugs. Med Lett Drugs Ther 2016;58:133-140.
8. Sterrett J, Corvino M, Avrett A, et al. Dyslipidemia drug update and guidelines review. https://scpa.memberclicks.net/assets/journalce/dyslipidemia%20drug%20update%2016-018.pdf. Accessed October 22, 2017.
9. Brookes ZL, McGown CC, Reilly CS. Statins for all: the new premed? Br J Anaesth 2009;103:99-107.
10. Ose L. Pitavastatin: a distinctive lipid-lowering drug. Clin Lipidol 2010;5:309-323.
11. Hennekens CH, Gelb IJ. Utilization of statins: guiding principles and the new United States guidelines. Cardiology 2014;128:41-42.
12. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25 Pt B):2889-2934.
13. Pichandi S, Pasupathi P, Raoc YY, et al. The role of statin drugs in combating cardiovascular diseases. Int J Cur Sci Res 2011;1:47-56.
14. Pella D, Rybar R, Mechirova V. Pleiotropic effects of statins. Acta Cardiol Sin 2005;21:190-198.
15. Wilmot KA, Khan A, Krishnan S, et al. Statins in the elderly: a patient-focused approach. Clin Cardiol 2015;38:56-61.
16. Hu M, Cheung BM, Tomlinson B. Safety of statins: an update. Ther Adv Drug Saf 2012;3:133-144.
17. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109(23 Suppl 1):III50-III57.
18. Graveline D. Adverse effects of statin drugs: a physician patient’ perspective. http://www.jpands.org/vol20no1/graveline.pdf. Published 2015. Accessed October 22, 2017.
19. Maji D, Shaikh S, Solanki D, et al. Safety of statins. Indian J Endocrinol Metab 2013;17:636-646.
20. Bitzur R, Cohen H, Kamari Y, et al. Intolerance to statins: mechanisms and management. Diabetes Care 2013;36(Suppl 2):S325-S330.
21. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008;8:373-418.
22. Gillett RC, Jr Norrell A. Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicity. Am Fam Physician 2011;83:711-716.
23. de Denus S, Spinler SA, Miller K, et al. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004;24:584-591.
24. Korth CE, Backes JM. Hepatotoxic effects of lipid-altering agents. US Pharm 2012;37:HS17-HS20.
25. Bjö ES. Hepatotoxicity of statins and other lipid-lowering agents. Liver Int 2017;37:173-178.
26. Bader T. The myth of statin-induced hepatotoxicity. Gastroenterology 2010;105:978-980.
27. Bjö E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol 2012;56:374-380.
28. Fernandez G, Spatz ES, Jablecki C, et al. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med 2011;78:393-403.
29. Kolovou V, Bilianou H, Kolovou G. Safe use of statins: focus on muscle toxicity. http://www.tandfonline.com/doi/full/10.1080/17584299.2016.1239873. Published October 14, 2016. Accessed October 22, 2017.
30. Chavez LO, Leon M, Einav S, et al. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care 2016;20:135.
31. Shannon J, John S, Ferrara J, et al. Statin-associated myopathy. US Pharm 2012;37:55-59.
32. Harper CR, Jacobson TA. Avoiding statin myopathy: understanding key drug interactions. Clin Lipidol 2011;6:665-674.
33. Deichmann R, Lavie C, Andrews S. Coenzyme q10 and statin-induced mitochondrial dysfunction. Ochsner J 2010;10:16-21.
34. Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev 2012;40:188-194.
35. Rosenson RS, Baker SK, Jacobson TA, et al. An assessment by the statin Muscle Safety Task Force: 2014 update. Clin Lipidol 2014;8(3 Suppl):S58-S71.
36. Mombelli G, Pavanello C. Statin muscle toxicity and genetic risk factors. Int J Genomic Med 2013;1:111.
37. Causevic-Ramosevac A, Semiz S. Drug interactions with statins. Acta Pharm 2013;63:277-293.
38. Wiggins BS, Sasseen JJ, Page RL, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2016;134:e468-e495.
39. Gavronski M, Volmer D, Hartikainen S, et al. Potential drug interactions with statins: Estonian register-based study. Open Med (Wars) 2015;10:254-260.
40. Bellosta S, Corsini A. Statin drug interactions and related adverse reactions. Expert Opin Drug Saf 2012;11:933-946.
41. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009;158:693-705.
42. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharm Ther 2010;87:130-133.
